Scarica l'app Stockscreener
467.89
0.28%
1.4886
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$466.40
Aprire:
$466.4
Volume 24 ore:
292.55K
Relative Volume:
0.40
Capitalizzazione di mercato:
$10.81B
Reddito:
$3.08B
Utile/perdita netta:
$1.24B
Rapporto P/E:
18.27
EPS:
25.6108
Flusso di cassa netto:
$1.07B
1 W Prestazione:
+3.03%
1M Prestazione:
+7.93%
6M Prestazione:
+53.17%
1 anno Prestazione:
+28.75%
Intervallo 1D:
$463.93
$476.70
Intervallo di 1 settimana:
$449.58
$476.70
Portata 52W:
$266.98
$479.50
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Confronta UTHR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
467.75 | 20.08B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
118.96 | 53.24B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 45.14B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.65 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
VTRS
Viatris Inc
|
10.69 | 12.35B | 14.33B | -3.79B | 1.84B | -3.17 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
How United Therapeutics Corporation (UTH) stock trades after earningsJuly 2025 Review & Technical Pattern Alert System - newser.com
Can technical indicators confirm United Therapeutics Corporation’s reversal2025 Technical Patterns & Risk Adjusted Swing Trade Ideas - newser.com
Why United Therapeutics Corporation stock is trending among retail traders2025 Key Highlights & Entry Point Confirmation Alerts - newser.com
Understanding United Therapeutics Corporation’s price movementPortfolio Risk Summary & Real-Time Sentiment Analysis - newser.com
How United Therapeutics Corporation (UTH) stock reacts to stronger dollarRecession Risk & Risk Controlled Stock Alerts - newser.com
Rothblatt (United Therapeutics) sells $4.7m in UTHR stock By Investing.com - Investing.com Canada
Heatmap analysis for United Therapeutics Corporation and competitorsJuly 2025 Price Swings & Breakout Confirmation Alerts - newser.com
United Therapeutics Executives Sell Shares Worth Over $13 Million - TradingView
Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR] - TradingView
3 Reasons Investors Love United Therapeutics (UTHR) - Finviz
United Therapeutics (UTHR): Stock Up 44.4%, Strong Growth & Cash FlowNews and Statistics - IndexBox
Is United Therapeutics Corporation (UTH) stock a top dividend aristocrat candidateJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Will United Therapeutics Corporation stock rally after Fed decisionsJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
United Therapeutics’ AI-Driven Study: A Potential Game-Changer for Pulmonary Hypertension Diagnosis - MSN
United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation - MSN
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
United Therapeutics CorporationCommon Stock (Nasdaq:UTHR) Stock Quote - Markets Financial Content
P/E Ratio Insights for United Therapeutics - Benzinga
Is United Therapeutics Corp Gaining or Losing Market Support? - Sahm
United Therapeutics Corporation (UTHR) Stock Forecasts - Yahoo! Finance Canada
UBS Maintains United Therapeutics (UTHR) Buy Recommendation - Nasdaq
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
United Therapeutics (NASDAQ:UTHR) CEO Sells $1,753,200.00 in Stock - MarketBeat
United Therapeutics CFO Sells Over $9 Million in Company Stock - TradingView
Will United Therapeutics Corporation stock benefit from upcoming earnings reportsQuarterly Investment Review & Advanced Technical Signal Analysis - newser.com
Access Investment Management LLC Makes New $2.14 Million Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ: UTHR) sets Nov 10 & 18 talks at UBS, Jefferies; webcasts - Stock Titan
United Therapeutics Corporation $UTHR Position Lessened by Bessemer Group Inc. - MarketBeat
Combining machine learning predictions for United Therapeutics CorporationMarket Performance Recap & Verified Technical Trade Signals - newser.com
United Therapeutics Corporation (UTHR) Stock forecasts - Yahoo Finance UK
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease - The Joplin Globe
United Therapeutics (Nasdaq: UTHR) starts EXPAND with first UKidney xenotransplant - Stock Titan
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock - MarketBeat
United Therapeutics Hits Day High with 9.63% Surge in Stock Price - Markets Mojo
MSN Money - MSN
United Therapeutics Corp. Hits New 52-Week High of $479.50 - Markets Mojo
United Therapeutics posts record revenue but misses Q3 earnings expectations - MSN
Focus Partners Advisor Solutions LLC Buys Shares of 1,440 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
3rd Circ. Preview: BMW, MiLB And Sandoz Top Nov. Lineup - Law360
United Therapeutics (NASDAQ:UTHR) Given New $423.00 Price Target at Wells Fargo & Company - MarketBeat
Assetmark Inc. Boosts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Grows Revenue, But Misses Earnings Forecast - Finimize
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Wells Fargo Maintains United Therapeutics (UTHR) Equal-Weight Recommendation - Nasdaq
United Therapeutics (NASDAQ:UTHR) Reaches New 12-Month High After Better-Than-Expected Earnings - MarketBeat
United Therapeutics price target raised to $587 from $569 at RBC Capital - TipRanks
United Therapeutics price target raised to $447 from $435 at Morgan Stanley - TipRanks
United Therapeutics (UTHR) Earnings Transcript - AOL.com
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 12 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 13 '25 |
Option Exercise |
120.26 |
4,000 |
481,040 |
4,130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 13 '25 |
Sale |
728.96 |
4,000 |
2,915,859 |
130 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Nov 12 '25 |
Sale |
460.00 |
4,000 |
1,839,996 |
130 |
0.95%
7.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):